COBRE/Tropical Medicine Seminar

May 20, 12:00pm - 1:00pm
Mānoa Campus, John A. Burns School of Medicine, Kaka’ako Campus, 651 Ilalo Street, MEB Auditorium (Room 315) Add to Calendar

"Antiviral Activity of Favipiravir Against Henipaviruses" by Alexander Freiberg, Ph.D., Assistant Professor, Department of Pathology, Director, Robert E. Shope BSL-4 Laboratory, University of Texas Medical Branch, Galveston, Texas Nipah virus (NiV) and Hendra virus are recently emerged bat-borne paramyxoviruses of the Henipavirus genus which cause severe acute respiratory and encephalitic diseases in humans. The case-fatality rate ranges from 40-90%, depending on the size of the outbreak. Currently, no vaccines or therapeutics are approved for use in humans. Favipiravir (T-705) is an RNA-dependent RNA polymerase inhibitor that has been approved for use against influenza virus in Japan and has displayed broad-spectrum efficacy against multiple RNA viruses (including filo-, arena- and bunyaviruses). Here, we demonstrate the in vitro activity of T-705 against henipaviruses and in vivo efficacy in a small animal model for NiV.


Event Sponsor
Pacific Center for Emerging Infectious Diseases Research/JABSOM Tropical Med., Mānoa Campus

More Information
Cori Watanabe, (808) 692-1654, corit@hawaii.edu, Freiberg seminar (PDF)

Share by email